Related Experiment Videos

[Association analysis between polymorphisms of PON gene cluster with coronary heart disease in Chinese]

Xiao-Ling Wang1, Zhong-Jie Fan, Jian-Feng Huang

  • 1Division of Population Genetics and Prevention, Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100037, China. wangxl_74@yahoo.com

Yi Chuan Xue Bao = Acta Genetica Sinica
|August 5, 2005
PubMed

Insights

This study found that specific variations in the PON1 gene, namely the -162G/A and R160G polymorphisms, are independently linked to coronary heart disease (CHD) in the Chinese Han population. These genetic factors may play a role in CHD development.

Area of Science:

  • Genetics
  • Cardiovascular Disease Research
  • Population Genetics

Background:

  • The paraoxonase gene cluster (PONs) plays a role in lipid metabolism and antioxidant defense.
  • Genetic variations within PON genes are potential risk factors for cardiovascular diseases like coronary heart disease (CHD).

Purpose of the Study:

  • To investigate the association between polymorphisms in the PON1, PON2, and PON3 genes and coronary heart disease (CHD) in the Chinese Han population.
  • To identify specific genetic variations within the PON gene cluster that are significantly associated with CHD risk.

Main Methods:

  • An association analysis was conducted on 474 male CHD patients and 475 controls from the Chinese Han population.
  • Eleven polymorphisms across PON1, PON2, and PON3 genes were genotyped.
  • Univariate, logistic regression, and haplotype analyses were performed to assess genetic associations.

Main Results:

  • Univariate analyses indicated higher frequencies of PON1 192Q, 160R, -162A alleles and PON2 311C in CHD cases.
  • Logistic regression identified PON1 R160G and -162G/A polymorphisms as significantly associated with CHD (P = 0.0054 and P = 0.0002, respectively).
  • Haplotype analyses confirmed that haplotypes containing the -162A allele were more frequent in cases, while those with the 160G allele were less frequent.

Conclusions:

  • The PON1 -162G/A and R160G polymorphisms are independently associated with coronary heart disease in the Chinese Han population.
  • These findings highlight the role of specific PON1 gene variations in CHD susceptibility.
  • Further research is warranted to elucidate the underlying biological mechanisms linking these polymorphisms to CHD.

Related Concept Videos

Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...